Form 4: 10x Genomics CEO Sells Shares for Tax Obligations

10x Genomics CEO Serge Saxonov sold 9,348 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), reported a sale of Class A Common Stock.
• The transaction, dated August 22, 2025, involved the disposition of 9,348 shares at a price of $13.787 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Saxonov directly beneficially owns 945,892 shares of Class A Common Stock.
• He also indirectly beneficially owns additional shares through various trusts: 27 shares via the Andromeda Trust, 89,825 shares via the Sirius Trust, 213,250 shares via the Y/S Descendants' Trust, and 58,000 shares via the Y/S Pot Trust.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax withholding obligations upon the vesting of restricted stock units, which is a common practice and does not indicate a change in management's outlook or company performance.

Positives

• The vesting of restricted stock units indicates that employee compensation and retention mechanisms are functioning as intended, aligning executive incentives with company performance.

Future Outlook

NA

Management Comments

• The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

NA

Related Party Transactions

• Serge Saxonov serves as trustee for the Andromeda Trust, Sirius Trust, Y/S Descendants' Trust, and Y/S Pot Trust, which indirectly hold shares of 10x Genomics, Inc.

Stakeholder Impact

• Shareholders: A minor dilution effect from the sale, but the transaction is routine and unlikely to significantly impact investor sentiment.
• Employees: The vesting of restricted stock units indicates the company's compensation structure is functioning as intended, potentially boosting employee morale and retention.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of shares by the CEO to cover tax obligations related to RSU vesting. This is a common and expected event for executive compensation and does not reflect a change in the company's fundamentals or management's long-term view. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

10x Genomics, TXG, Serge Saxonov, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding